Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter.

100ATGB AAV5 AAV5-hFVIII-SQ ER stress endoplasmic reticulum gene therapy hemophilia A hybrid liver-specific promoter molecular chaperone valoctocogene roxaparvovec

Journal

Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857

Informations de publication

Date de publication:
11 Sep 2020
Historique:
received: 06 04 2020
accepted: 06 07 2020
entrez: 11 8 2020
pubmed: 11 8 2020
medline: 11 8 2020
Statut: epublish

Résumé

Adeno-associated virus 5 (AAV5)-human factor VIII-SQ (hFVIII-SQ; valoctocogene roxaparvovec) is an AAV-mediated product under evaluation for treatment of severe hemophilia A, which contains a B-domain-deleted hFVIII (hFVIII-SQ) transgene and a hybrid liver-specific promotor (HLP). To increase FVIII-SQ expression and reduce the vector dose required, a stronger promoter may be considered. However, because FVIII-SQ is a protein known to be difficult to fold and secrete, this could potentially induce endoplasmic reticulum (ER) stress. We evaluated the effect of two AAV5-hFVIII-SQ vectors with different liver-specific promoter strength (HLP << 100ATGB) on hepatic ER stress in mice. Five weeks after receiving vehicle or vector, the percentage of transduced hepatocytes and levels of liver hFVIII-SQ DNA and RNA increased dose dependently for both vectors. At lower doses, plasma hFVIII-SQ protein levels were higher for 100ATGB. This difference was attenuated at the highest dose. For 100ATGB, liver hFVIII-SQ protein accumulated dose dependently, with increased expression of ER stress markers at the highest dose, suggesting hepatocytes reached or exceeded their capacity to fold/secrete hFVIII-SQ. These data suggest that weaker promoters may require relatively higher doses to distribute expression load across a greater number of hepatocytes, whereas relatively stronger promoters may produce comparable levels of FVIII in fewer hepatocytes, with potential for ER stress.

Identifiants

pubmed: 32775496
doi: 10.1016/j.omtm.2020.07.005
pii: S2329-0501(20)30154-6
pmc: PMC7397702
doi:

Types de publication

Journal Article

Langues

eng

Pagination

620-630

Informations de copyright

© 2020 The Authors.

Références

Mol Ther. 2015 Jan;23(1):192-201
pubmed: 25322757
Lancet. 2016 Jul 9;388(10040):187-97
pubmed: 26897598
J Clin Med. 2019 Oct 26;8(11):
pubmed: 31717752
PLoS One. 2012;7(12):e51290
pubmed: 23236464
Biochem Soc Trans. 2014 Dec;42(6):1752-5
pubmed: 25399601
Sci Rep. 2017 Mar 22;7:45033
pubmed: 28327546
Toxicol Appl Pharmacol. 2015 Mar 15;283(3):157-67
pubmed: 25620058
Mol Cell Proteomics. 2015 May;14(5):1400-10
pubmed: 25724911
Dis Markers. 2015;2015:814670
pubmed: 26265795
Int J Mol Med. 2018 Apr;41(4):2233-2242
pubmed: 29393386
Mol Cell Proteomics. 2014 Dec;13(12):3698-708
pubmed: 25360005
Arch Ophthalmol. 2012 Jan;130(1):9-24
pubmed: 21911650
Mol Ther Methods Clin Dev. 2016 Sep 28;3:16064
pubmed: 27738645
Blood. 2013 Feb 7;121(6):1039-48
pubmed: 23243272
N Engl J Med. 2017 Dec 28;377(26):2519-2530
pubmed: 29224506
Int J Clin Exp Pathol. 2018 Nov 01;11(11):5223-5231
pubmed: 31949602
Cell Rep. 2018 Oct 2;25(1):212-223.e4
pubmed: 30282030
J Biol Chem. 1999 Nov 12;274(46):32539-42
pubmed: 10551804
Ann Intern Med. 2019 Oct 15;171(8):540-546
pubmed: 31499529
PLoS One. 2010 Sep 29;5(9):
pubmed: 20927376
Blood. 2004 May 1;103(9):3412-9
pubmed: 14726380
J Proteome Res. 2006 Feb;5(2):277-86
pubmed: 16457593
Blood. 2013 Apr 25;121(17):3335-44
pubmed: 23426947
Mol Ther. 2018 Feb 7;26(2):496-509
pubmed: 29292164
Blood Adv. 2019 Mar 12;3(5):825-838
pubmed: 30862611
Sci Rep. 2018 Aug 15;8(1):12179
pubmed: 30111770
Hepatology. 2011 Jul;54(1):229-39
pubmed: 21503947
Nat Cell Biol. 2000 Jun;2(6):326-32
pubmed: 10854322
Mol Ther. 2018 Oct 3;26(10):2337-2356
pubmed: 30093306
Methods Enzymol. 2011;490:71-92
pubmed: 21266244
Blood. 2020 May 21;135(21):1899-1911
pubmed: 32128578
N Engl J Med. 2014 Nov 20;371(21):1994-2004
pubmed: 25409372
J Thromb Haemost. 2014 Jan;12(1):36-42
pubmed: 24118899
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18525-30
pubmed: 19011102
Arthritis Rheum. 2004 Apr;50(4):1164-71
pubmed: 15077298
Proc Natl Acad Sci U S A. 1990 Oct;87(19):7429-32
pubmed: 2120699
N Engl J Med. 2020 Jan 2;382(1):29-40
pubmed: 31893514
Nat Med. 2006 Mar;12(3):342-7
pubmed: 16474400
Genes Dev. 1989 Jul;3(7):1019-25
pubmed: 2570734
Mol Ther Methods Clin Dev. 2016 Sep 28;3:16063
pubmed: 27738644
Oncotarget. 2017 Mar 21;8(12):19354-19364
pubmed: 28423613
Mol Ther Methods Clin Dev. 2016 Mar 16;3:16002
pubmed: 27014711
Mol Ther. 2012 Oct;20(10):1968-80
pubmed: 22692499

Auteurs

Sylvia Fong (S)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Britta Handyside (B)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Choong-Ryoul Sihn (CR)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Su Liu (S)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Lening Zhang (L)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Lin Xie (L)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Ryan Murphy (R)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Nicole Galicia (N)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Bridget Yates (B)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Wesley C Minto (WC)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Catherine Vitelli (C)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Danielle Harmon (D)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Yuanbin Ru (Y)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Guoying Karen Yu (GK)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Claudia Escher (C)

Biognosys AG, Schlieren, Switzerland.

Jakob Vowinckel (J)

Biognosys AG, Schlieren, Switzerland.

Jill Woloszynek (J)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Hassib Akeefe (H)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Rajeev Mahimkar (R)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Sherry Bullens (S)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Stuart Bunting (S)

BioMarin Pharmaceutical, Inc., Novato, CA, USA.

Classifications MeSH